Clinical data demonstrate that co-testing with Pap and HPV ordered together on the same accession provides the best protection against ≥CIN3 and cervical cancer for women ages 30 to 65, and recommendations from multiple leading health organizations support this conclusion. The results are in: co-testing is the most sensitive option for the most complete care.
A landmark study from Quest Diagnostics HealthTrends™ used co-testing and cervical biopsy results to retrospectively compare Pap-alone testing, HPV-alone testing, and co-testing. The national study analyzed the de-identified data of approximately 8.6 million women ages 30 to 65 from thousands of clinical practices.1,2
- Study population included 256,648 women who received both a co-test (Pap and HPV ordered together on the same accession) and cervical cancer biopsy performed by Quest Diagnostics within 1 year of each other
- Visit GoWithCotesting.com to download a copy of the HealthTrends study by Blatt AJ, et al, from the May 2015 issue of Cancer Cytopathology
Numerous studies have shown screening with HPV alone misses cervical cancer in up to 31% of cases.1,2
- Clinical data from 10 published studies, including the Quest Diagnostics HealthTrends study, show that co-testing (Pap and HPV ordered together on the same accession) offers the best protection for your patients1,2
1. Blatt AJ, Kennedy R, Luff RD, et al. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathology. 2015;123(5):282-288.
2. Quest Diagnostics. Data on file. 2015.